Background Our understanding of coronavirus disease 2019 (COVID-19) and its
implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We …

Abstract Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2), represents one of the biggest challenges of 21st …

Background and Aims. The impact of COVID‐19 has been of great concern in patients with
inflammatory bowel disease (IBD) worldwide, including an increased risk of severe …

Abstract Background and Aims Age is a major prognostic factor for COVID-19 outcomes. The
effect of inflammatory bowel disease [IBD] activity on COVID-19 is unclear. We examined the …

Background Limited data exist regarding the disease course of coronavirus disease 2019
(COVID-19) and its relationship with immunosuppressants among patients with immune …

Background There are concerns that individuals with chronic immune‐mediated diseases
are at increased risk of COVID‐19 and related severe adverse outcome, including intensive …

The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

The susceptibility, risk factors, and prognosis of COVID‐19 in patients with inflammatory
bowel disease (IBD) remain unknown. Thus, our study aims to assess the prevalence and …

Summary Background Recently, the SECURE‐IBD study, based on a physician‐reported
registry, suggested that thiopurines, either alone or combined with anti‐TNF, may increase …

There is conflicting evidence concerning the effect of inflammatory bowel disease (IBD) on
COVID-19 incidence and outcome. Hence, we aimed to evaluate the published evidence …